SIGLEC1 and neoplasm: In our previous studies we have investigated the efficacy of Ag targeting to CD169+ macrophages in mouse models and demonstrated induction of strong effector and memory CD8+ T cell responses and suppression of tumor outgrowth after either OVA protein or SIINFEKL peptide targeting in the presence of a strong adjuvant [31].